Expert Ratings for Arcus Biosciences
Portfolio Pulse from Benzinga Insights
Arcus Biosciences (NYSE:RCUS) has received mostly bullish ratings from analysts in the last quarter, with 5 bullish, 4 somewhat bullish, and 1 indifferent rating. The average 12-month price target for the stock, according to 10 analysts, is $46.5, with a high of $70.00 and a low of $23.00. This average price target has increased by 36.76% over the past month.
October 03, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcus Biosciences has received mostly bullish ratings from analysts, indicating a positive outlook for the stock. The average 12-month price target has also increased significantly over the past month.
The majority of analyst ratings for Arcus Biosciences are bullish, indicating a positive outlook for the stock. Additionally, the average 12-month price target has increased by 36.76% over the past month, suggesting that analysts believe the stock has significant growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100